Illumina, Inc. $ILMN Stake Decreased by Eagle Health Investments LP

Eagle Health Investments LP reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 28.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 231,161 shares of the life sciences company’s stock after selling 91,100 shares during the period. Illumina accounts for about 6.7% of Eagle Health Investments LP’s investment portfolio, making the stock its 5th largest position. Eagle Health Investments LP’s holdings in Illumina were worth $30,319,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Illumina by 17.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after acquiring an additional 124,246 shares during the period. Elo Mutual Pension Insurance Co purchased a new position in shares of Illumina during the 3rd quarter worth about $2,319,000. Caprock Group LLC purchased a new position in shares of Illumina during the 3rd quarter worth about $1,479,000. Rakuten Investment Management Inc. purchased a new position in shares of Illumina during the 3rd quarter worth about $861,000. Finally, Capital World Investors lifted its holdings in shares of Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after acquiring an additional 3,331,542 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ILMN. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. JPMorgan Chase & Co. raised their price target on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Weiss Ratings lowered shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Guggenheim raised their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $137.75.

Insider Buying and Selling

In other news, Director Keith A. Meister sold 104,393 shares of Illumina stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the sale, the director owned 3,500,048 shares in the company, valued at $508,696,976.32. This trade represents a 2.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 330,160 shares of company stock worth $48,028,308 in the last quarter. Insiders own 2.90% of the company’s stock.

Illumina Trading Up 0.2%

NASDAQ ILMN opened at $141.92 on Thursday. Illumina, Inc. has a one year low of $78.55 and a one year high of $155.53. The company’s 50 day moving average price is $129.54 and its 200 day moving average price is $130.66. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a market capitalization of $21.47 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.35 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm posted $0.97 earnings per share. Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 5.2 EPS for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.